The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mosolov S.N.

Moskovskiĭ NII psikhiatrii Roszdrava

Actual theoretical problems of diagnostic, classification, neurobiology and therapy of schizophrenia: a comparison of International and Russian experience

Authors:

Mosolov S.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(6): 4‑11

Read: 4492 times

Download PDF (RU)
Contact the author
Table of contents

ACTUAL THEORETICAL PROBLEMS OF DIAGNOSTIC, CLASSIFICATION, NEUROBIOLOGY AND THERAPY OF SCHIZOPHRENIA: A COMPARISON OF INTERNATIONAL AND RUSSIAN EXPERIENCE
ACTUAL THEORETICAL PROBLEMS OF DIAGNOSTIC, CLASSIFICATION, NEUROBIOLOGY AND THERAPY OF SCHIZOPHRENIA: A COMPARISON OF INTERNATIONAL AND RUSSIAN EXPERIENCE

To cite this article:

Mosolov SN. Actual theoretical problems of diagnostic, classification, neurobiology and therapy of schizophrenia: a comparison of International and Russian experience. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(6):4‑11. (In Russ.)

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Difficulties in life­time diagnosis of Creutzfeldt—Jakob disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):19-27
The role of immuno-inflammatory factors in the deve­lopment of nega­tive symptoms in schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):42-48
A role of transcription factors in pathogenic processes asso­ciated with schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):49-54
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Meta­bolic syndrome and anti­psychotic therapy of schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):165-170
Neuronal models based on olfa­ctory epithelial cells in the study of the pathogenesis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):20-25
Therapeutic and diagnostic classification of dege­nerative spondylolisthesis: vali­dation and multiple-center inter-observer agreement. Burdenko's Journal of Neurosurgery. 2024;(6):13-22
Clinical case of auri­cular gouty tophi. Russian Bulletin of Otorhinolaryngology. 2024;(6):80-84
Dete­ction of mpox virus by enzyme immu­noassay in a no-instrumental format and after its inactivation with formaldehyde. Mole­cular Gene­tics, Microbiology and Viro­logy. 2024;(4):49-53
Labo­ratory diagnostics of monkeypox: basic methods and prospects for new deve­lopments. Labo­ratory Service. 2024;(4):57-64
Abstract:

Keywords:

shizophrenia
diagnostics
classification
neurobiology
therapy

Authors:

Mosolov S.N.

Moskovskiĭ NII psikhiatrii Roszdrava

Close metadata

References:

  1. Gofman A.G. (red.) Psikhiatriya. Spravochnik prakticheskogo vracha. M: Medpressinform 2006; 591.
  2. Dzhons P., Bakli P. Shizofreniya. M: Medpressinform 2008; 192.
  3. Mosolov S.N. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsiya negativnykh i pozitivnykh rasstroistv. M: Novyi tsvet 2001; 238.
  4. Polyakov Yu.F. Patologiya poznavatel'noi deyatel'nosti pri shizofrenii. M: Meditsina 1974; 168.
  5. Snezhnevskii A.V. (red.) Rukovodstvo po psikhiatrii. M: Meditsina 1983; 1: 299.
  6. Tiganov A.S. (red.) Rukovodstvo po psikhiatrii. T. 1. M: Meditsina 1999.
  7. Uotson D. DNK i mozg (v poiskakh genov psikhicheskikh zabolevanii). Lektsiya 3 iyulya 2008g. v Moskve. http://elementy.ru/lib/430639.
  8. Ahmed Iqbal Fujii Daryl. The spectrum of psychoyic disorders: neurobiology, etiology, and psthogenesis. Cambridge, UK: Cambridge University Press 2007.
  9. Andreasen N.C. Negative symptoms in schizophrenia. Arch Gen Psychiat 1982; 39: 784-788.
  10. Andreasean N.C. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995; 346: 477-481.
  11. Arts B., Jabben N., Krabbendam L. et al. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives. Psychol Med 2008; 38: 771-785.
  12. Awad A.G., Voruganti L.N. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics 2008; 26: 2: 149-162.
  13. Benes F.M., Davidson J., Bird E.D. Quantiative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiat 1986; 43: 1: 31-35.
  14. Berridge K.C., Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Rev 1998; 28: 309-369.
  15. Bora et al. Cognitive impairment in schizophrenia and affective psychoses: implications for DSM-V criteria and beyond. Schizophr Bull 2010; 36: 36-42.
  16. Buchanan R.W., Carpenter W.T. Schizophrenia. Introduction and overview. In: B. Kaplan, V. Sadock. Comprehensive textbook of psychiatry. 7th edition; I. Philadelphia, Lippincotte, Williams and Wilkins 2000; 1096-1110.
  17. Buckholtz J.W., Callicott J.H., Kolachana B. et al. Genetic variation in MAOA modulates ventromedial prefrontal circuity mediating individual differences in human personality. Mol Psychiat 2008; 13: 3: 313-324.
  18. Callicott J.H., Straub R.E., Pezawas L. et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 2005; 102: 24: 8627-8632.
  19. Cannon T.D., Hennah W., van Erp T.G. et al. Association of DISC1/TRAX halotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiat 2005; 62: 11: 1205-1213.
  20. Collier D.A. Schizophrenia: the polygene princess and the pea. Psychol Med 2008; 1-5.
  21. Crow T.J. The two syndrome concept, origins and current status. Schizophr Bull 1985; 11: 471-477.
  22. Crow T.J. How and why genetic linkage has not solved the problem of psychosis: rewiew and hypothesis. Am J Psychiat 2007; 164: 13-21.
  23. Crow T.J. The emperors of the schizophrenia polygene have no clothes. Psychol Med 2008; 1-5.
  24. Cuesta M.J., Peralta V., Zarzuela A. Empirical validation of competing definitions of schizophrenia: a poly-diagnostic study of cognitive impairment in non-affective psychosis. Schizophr Res 2007; 95: 39-47.
  25. Davis J., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiat 2003; 60: 6: 553-564.
  26. Faraone S.V., Seidman I.J., Kremen W.S. et al. Neuropsychologic functioning among the nonspecific relatives of schizophrenic patients: a four-year follow up study. J Abnorm Psychol 1999; 108: 176-181.
  27. Jackson J.H. Selected writings. Holder and Stoughton. London 1931; 1: 411.
  28. Geddes J., Freemantle N., Harrison P. et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and regression analysis. BMJ 2000; 321: 1371-1376.
  29. Goldberg T.E., Straub R.E., Callicott J.H. et al. The G72/G30 gene complex and cognitive abnormalities in schizophrenia. Neuropsychopharmacology 2006; 31: 9: 2022-2032.
  30. Green M.F., Kern R.S., Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004; 72: 1: 41-51.
  31. Griesinger W. Die Pathologic und Therapie der psychischen Krankheiten. Braunsduweig: Verlag von Friedrich Wreden 1871; 53-85.
  32. Hall J., Whalley H.C., Job D.E. et al. A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nat Neurosci 2006; 9: 12: 1477-1478.
  33. Heinrichs R.W. The primacy of cognition in schizophrenia. Am Psychol 2005; 60: 3: 229-242.
  34. Henquet C., Di Forti M., Morrison P. et al. Gene-Environment Interplay Between Cannabis and Psychosis. Schizophr Bull 2008; 34: 6: 1111-1121.
  35. Hill S.K., Keshavan M.S., Thase M.E. et al. Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression. Am J Psychiat 2004; 161: 6: 996-1003.
  36. Hoche A. Die Medizin der Gegenwart in Sellbstdarstellungen, 1925.
  37. Huber G. Konzept substratnaher Basis Symptome und seine Bedentung fur Theorie und Therapie Schizophrener Erkrankungen. Nervenarrt 1982; 54: 1: 23-32.
  38. Kaplan B., Sadock V. Handbook of clinical psychiatry. 4th ed. Williams, Wilkins 1998; 505.
  39. Kapur S. Psychosis as a state of aberrant salience: a framenork linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiat 2003; 160: 1: 13-23.
  40. Kapur S., Mizrahi M., Li M. From dopamine to salience to psychosis - linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2009; 79: 1: 59-68.
  41. Kay S.R., Singh M.M. Cognitive abnormality in schizophrenia: A dual process model. Biol Psychiat 1979; 14: 155-176.
  42. Keefe R.S., Eesley C.E., Poe M.P. Defining a cognitive function decrement in schizophrenia. Biol Psychiat 2005; 57: 6: 688-692.
  43. Keefe R.S., Fenton W.S. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007; 33: 4: 912-920.
  44. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A Separate Disease within the Syndrome of Schizophrenia. Arch Gen Psychiat 2001; 58: 165-171.
  45. Leucht S., Barnes T.R., Kissling W. et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review of exploratory meta-analysis of randomized, controlled trials. Am J Psychiat 2003; 160: 7: 1209-1222.
  46. Leucht S., Corves C., Arbter D. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
  47. Leucht S., Komossa K., Pummel-Kluge C. et al. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiat 2009; 166: 2.
  48. Lieberman J.A., Stroup T.S., McEvoy J.P. et al. Effectiveness of Antipsychotic Drugs in Chronic Schizopfrenia. Engl J Med 2005; 353: 12: 1209-1223.
  49. McCarthy S.E., Makarov V., Kirov G. et al. Microduplications of 16p11.2 are associated with schizophrenia". Nature Genetics 2009; 41: 11: 1223-1227.
  50. McClellan J.M., Susser E., King M.C. Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiat 2007; 3: 190: 194-199.
  51. Mc Evoy M. et al. Poster presented at Annual New Clinical Drug Evaluation Unit Meeting, June 12-16, 2006, Boca Raton, Florida, USA.
  52. Molina V., Sanz J., Sarramea F. et al. Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiat Res 2004; 131: 1: 45-56.
  53. Murray R. Assessing symptom dimensions in psychosis: towards the diagnostic and statistical manual of mental disorders - V (DSM-V) and the international classification of diseases and health-related problems - (11th revision) (ICD-11). Presentation at satellite symposium "Treatment of schizophrenia: Towards a Comprehensive Approach" on the occasion of the 20th ECNP Congress, 16 October 2007; 1-12.
  54. Murray R.M., Sham P., van Os J. et al. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr Res 2004; 71: 405-416.
  55. Nakamura M., Salisbury D.F., Hirayasu Y. et al. Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol Psychiat 2007; 62: 7: 773-783.
  56. Nasrallah H.A., Keshavan M.S., Benes F.M. et al. Roceedings and Data From The schizophrenia Summit: a clinical appraisal to improve the management of schizophrenia. J Clin Psychiat 2009; 70: Suppl 1: 4-46.
  57. National Collaborating Centre for Mental Health: Schizophrenia. Full national clinical guidelines on core interventions in primary and secondary care. London: Gaskell and British Psychological Society 2003; 252.
  58. O'Donovan M.C., Cradock N., Owen M.J. Schizophrenia: complex genetics, not fairy tales. Psychol Med 2008; 1-3.
  59. Owen M.J., Craddock N., Jablensky A. The genetic deconstruction of psychosis. Schizophr Bull 2007; 33: 905-911.
  60. Peralta V., Cuesta M.J. Diagnostic significance of Schneider's first-rank symptoms in schizophrenia. Comparative study between schizophrenic and non-schizophrenic psychotic disorders. Br J Psychiat 1999; 174: 243-248.
  61. Purcell S.M., Wray N.R., Stone J.L. et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 8: 748-752.
  62. Rosenheck R., Perlick D., Bingham S. et al. European First Episode Trial (EUFEST) comparing Ziprazidone, Amisulpride, Quetiapine, Olanzapine and Haloperidol in a randomized open-label one-year design. Lancet 2007 (in press).
  63. Rossler W., Salize H. J., Van Os J. et al. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15: 4: 399-409.
  64. Rund B.R. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998; 24: 425-435.
  65. Sato M. Renaming schizophrenia: a Japanese perspective. World Psychiat 2006; 1: 53-55.
  66. Saykin A.J., Gur R.C., Gur R.E. et al. Neuropsychological function decrement in schizophrenia: selective impairment in memory and learning. Arch Gen Psychiat 1991; 48: 7: 618-624.
  67. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiat 1995; 52: 10: 805-818; discussion 819-820.
  68. Snitz B.E., Macdonald A.W., Carter C.S. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophr Bull 2006; 32: 1: 179-194.
  69. Straub R.E., Lipska B.K., Egan M.F. et al. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and expression. Mol Psychiat 2007; 12: 9: 854-869.
  70. Strauss J.S., Carpenter W.T., Bartko J.J. The diagnosis and understanding of schizophrenia: III. Speculations on the process that underlie schizophrenic symptoms and signs. Schizophr Bull 1974; 11: 61-76.
  71. Sullivan P.F. The dice are rolling for schizophrenia genetics. Psychol Med 2008; 1-4.
  72. Süllwold L. Symptome schizophrener Erkrankungen. Uncharakteristische Basisstörungen. - Mongraphien ans dem Gesamtgebiete der Psychiatrie. Bd 13. Berlin 1977.
  73. Tan H.Y., Nicodemus K.K., Chen Q. et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118: 6: 2200-2208.
  74. Tunbrige E.M., Harrison P.J., Weinberger D.R. Catechol-o-menthyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiat 2006; 60: 2: 141-151.
  75. van Haren N.E., Hulshoff Pol H.E., Schnack H.G. et al. Focal gray matter changes in schizophrenia across the course of the ilness: a 5-year follow-up study. Neuropsychopharmacology 2007; 32: 10: 2057-2066.
  76. van Os J. Salience syndrome replaces schizophrenia in DSM-V and ICD-11: psychiatry's evidence-based entry into the 21st century? Acta Psychiat Scand 2009; 120: 5: 363-372.
  77. van Os J. A salience dysregulation syndrome. Br J Psychiat 2009; 194: 2: 101-103.
  78. van Os J., Kapur S. Schizophrenia. Lancet 2009; 374: 9690: 635-645.
  79. Wildenauer D.B., Schwab S.G., Maier W et al. Do schizophrenia and affective disorder share succeptibility genes? Schizophr Res 1999; 39: 107-111.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.